Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

re information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... -- Though therapies are in their nascent phase, sales ... annual increase of 16.2% over the 2010-2020 period, reaching ... to Kalorama Information,s report, Stem Cell Therapeutics Markets ... have gained or are expected to gain approval from ... ever more complicated conditions, stem cell therapies hold the ...
(Date:10/30/2014)... 30, 2014 /CNW/ - Atlantic Canadians will save an ... Canada,s provinces and territories and ... of the Canadian Generic Pharmaceutical Association (CGPA), said today. ... speaking at the Atlantic Summit on Healthcare and Drug ... is being hosted by the Public Policy Forum and ...
(Date:10/30/2014)... -- Stryker Orthopaedics, the Official Joint Replacement Products of ... its debut year of the relationship at the Charles ... This marks the eleventh tournament stop along both ... has activated on-site with the "Stryker Mobility Zone" – ... importance of joint health.  The Stryker ...
Breaking Medicine Technology:Report: Stem Cell Technologies Market Growing 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4
... and Buffalo Grove, Ill. , May 11 Solta ... today announced that they have reached an agreement resolving lawsuits involving certain Thermage® ... , , ... U.S. District Court in Delaware by Alma Lasers seeking a declaration ...
... CrystalGenomics, Inc., a novel drug R&D company announced today that ... antibiotic candidate, CG400549, has been successfully completed in Europe . ... CG400549 is ... which is a critical enzyme in generating bacterial membrane) as it ...
Cached Medicine Technology:Solta Medical and Alma Lasers Resolve Patent Lawsuits 2Solta Medical and Alma Lasers Resolve Patent Lawsuits 3CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2
(Date:10/31/2014)... St. Joseph, Missouri (PRWEB) October 31, 2014 ... prepare for school, one Midwest optometrist feels they may ... vision problems to affect areas like concentration, school performance ... events may be too brief to identify progressive vision ... Options, St. Joseph, Mo., announces a new initiative: The ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Surgery for low ... where in the United States you live, a new ... experience low back pain at some point in their ... professional medical care for a spine problem," co-author Brook ... Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
(Date:10/31/2014)... North Shore Eye Care today announced ... Island and the addition of leading ophthalmologist, William S. ... North Shore Eye Care Medical Director, Jeffrey Martin, MD. ... the Department of Ophthalmology of Winthrop-University Hospital and has ... for more than 30 years. He has been named ...
Breaking Medicine News(10 mins):Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3
... , , SALT LAKE ... it has added 10 new sales representatives to its nationwide direct sales ... , , "We,re thrilled to be adding so ... vice president of sales and marketing at Dynatronics. "This is just ...
... , , EMERYVILLE, Calif., ... ) today announced that it will webcast an investor briefing ... Time. Speakers will review clinical data for Nexavar in breast ... 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress in ...
... , , C.S. Mott Children,s Hospital ... to have their children vaccinated against H1N1 flu, despite higher disease risk; ... ANN ARBOR, Mich., Sept. 24 With schools back in session, H1N1 ... children. A new vaccine against H1N1 flu -- strongly recommended for kids ...
... , , SAN ... company discovering and developing a new class of naturally occurring ... in Tokyo on Tuesday October 6. Jeff Watkins, CEO of ... product engine, and lead program based on naturally occurring resected ...
... N.J., Sept. 24 Marketing Technology Solutions , ... QualityHealth.com , has today filed a lawsuit alleging that ... misappropriated trade secrets and other confidential information by utilizing MTS-copyrighted online ... a health website owned and operated by MediZine. , , ...
... Singapore and Washington DC (September 24, 2009) There is clear ... cancer, according to a study published in the current issue ... The article "Lifestyle Interventions in the Prevention and Treatment ... common forms of cancer (lung, colorectal, breast, prostate and skin) ...
Cached Medicine News:Health News:Dynatronics Expands Nationwide Direct Sales Force by 25 Percent 2Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 2Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 3Health News:H1N1 Flu: Are Parents Underestimating Risk to Kids? 4Health News:aTyr Pharma to Present at Japan Biopharma Partnering Conference 2Health News:MediZine Named in Intellectual Property Lawsuit Filed by Marketing Technology Solutions 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: